Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
27.04 (1y: +33%)
Market Cap 1.71 B P/E(ttm) 421.90
Enterprise Value 1.63 B P/B 2.33
VPHM- NAS (USA)
ViroPharma, Inc.
  • Currently 1/5
Business Predictability Rank: 1-Star (On Watch)
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$27.04
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry		 vs
history
Cash to Debt 1.526
VPHM's Cash to Debt is ranked lower than
73% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 46.63 vs. VPHM: 1.526 )
VPHM' s 10-Year Cash to Debt Range
Min: 0.19   Max: No Debt
Current: 1.53
Equity to Asset 0.035
VPHM's Equity to Asset is ranked lower than
88% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 0.53 vs. VPHM: 0.035 )
VPHM' s 10-Year Equity to Asset Range
Min: -0.8   Max: 0.81
Current: 0.04
-0.8
0.81
Interest Coverage 2.5
VPHM's Interest Coverage is ranked lower than
61% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 37.90 vs. VPHM: 2.5 )
VPHM' s 10-Year Interest Coverage Range
Min: 3   Max: No Debt
Current: 2.5
F-Score: 2
Z-Score: 3.18
M-Score: -2.39
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry		 vs
history
Operating margin (%) 7.80
VPHM's Operating margin (%) is ranked higher than
72% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: -31.50 vs. VPHM: 7.80 )
VPHM' s 10-Year Operating margin (%) Range
Min: -31000   Max: 66.6
Current: 7.8
-31000
66.6
Net-margin (%) 1.3
VPHM's Net-margin (%) is ranked higher than
63% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: -29.90 vs. VPHM: 1.3 )
VPHM' s 10-Year Net-margin (%) Range
Min: -29500   Max: 85.9
Current: 1.3
-29500
85.9
ROE (%) 0.7
VPHM's ROE (%) is ranked higher than
63% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: -7.60 vs. VPHM: 0.7 )
VPHM' s 10-Year ROE (%) Range
Min: -210.4   Max: 34.8
Current: 0.7
-210.4
34.8
ROA (%) 0.5
VPHM's ROA (%) is ranked higher than
62% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: -10.10 vs. VPHM: 0.5 )
VPHM' s 10-Year ROA (%) Range
Min: -40.9   Max: 26.1
Current: 0.5
-40.9
26.1
ROC (Joel Greenblatt) (%) 32.30
VPHM's ROC (Joel Greenblatt) (%) is ranked higher than
87% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. VPHM: 32.30 )
VPHM' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1566.7   Max: 712.8
Current: 32.3
-1566.7
712.8
Revenue Growth (%) 10.4
VPHM's Revenue Growth (%) is ranked higher than
79% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. VPHM: 10.4 )
VPHM' s 10-Year Revenue Growth (%) Range
Min: -17.6   Max: 151
Current: 10.4
-17.6
151
EBITDA Growth (%) 5.5
VPHM's EBITDA Growth (%) is ranked higher than
79% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. VPHM: 5.5 )
VPHM' s 10-Year EBITDA Growth (%) Range
Min: -45.1   Max: 28.6
Current: 5.5
-45.1
28.6
» VPHM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

VPHM Guru Trades in Q2 2012

Joel Greenblatt 612,563 sh (+58.94%)
Chuck Royce 311,803 sh (unchged)
Murray Stahl 15,000 sh (unchged)
Louis Moore Bacon Sold Out
Steven Cohen Sold Out
Jim Simons Sold Out
Paul Tudor Jones Sold Out
Jeremy Grantham Sold Out
» More
Q3 2012

VPHM Guru Trades in Q3 2012

Pioneer Investments 424,673 sh (New)
Jeremy Grantham 11,100 sh (New)
Steven Cohen 58,944 sh (New)
Murray Stahl 15,000 sh (unchged)
Chuck Royce 311,003 sh (-0.26%)
Joel Greenblatt 360,905 sh (-41.08%)
» More
Q4 2012

VPHM Guru Trades in Q4 2012

Manning & Napier Advisors, Inc 200,300 sh (New)
Steven Cohen 253,420 sh (+329.93%)
Murray Stahl 15,000 sh (unchged)
Chuck Royce Sold Out
Pioneer Investments 386,000 sh (-9.11%)
Joel Greenblatt 227,509 sh (-36.96%)
» More
Q1 2013

VPHM Guru Trades in Q1 2013

Jim Simons 549,300 sh (New)
Steven Cohen 419,031 sh (+65.35%)
Manning & Napier Advisors, Inc 324,600 sh (+62.06%)
Murray Stahl 15,000 sh (unchged)
Pioneer Investments 376,430 sh (-2.48%)
Joel Greenblatt 183,556 sh (-19.32%)
» More
» Details

Insider Trades

Latest Guru Trades with VPHM

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2012-12-31 Reduce -36.96%0.27%$22.24 - $30.26 $ 27.046%227509
Joel Greenblatt 2012-09-30 Reduce -41.08%0.45%$19.86 - $30.71 $ 27.049%360905
Joel Greenblatt 2012-06-30 Add 58.94%0.41%$19.38 - $30.69 $ 27.0424%612563
Joel Greenblatt 2012-03-31 Add 60.91%0.38%$27.54 - $32.69 $ 27.04-5%385395
Joel Greenblatt 2011-12-31 Reduce -29.63%0.3%$17.64 - $28.04 $ 27.0422%239511
Joel Greenblatt 2011-06-30 Add 3161.34%0.83%$17.28 - $21.81 $ 27.0444%330276
Joel Greenblatt 2011-03-31 Reduce -96.24%1.54%$16.2 - $20.2 $ 27.0453%10127
Joel Greenblatt 2010-12-31 New Buy1.53%$14.45 - $18.19 $ 27.0465%269572
George Soros 2010-06-30 Sold Out $11.11 - $14.04 $ 27.04112%0
George Soros 2010-03-31 New Buy$8.31 - $14.11 $ 27.04143%15300
Premium More recent guru trades are included for Premium Members only!!

Ratios

vs
industry		 vs
history
P/E(ttm) 421.90
VPHM's P/E(ttm) is ranked lower than
97% of the 155 Companies
in the Global Biotechnology industry.

( Industry Median: 32.70 vs. VPHM: 421.90 )
VPHM' s 10-Year P/E(ttm) Range
Min: 4.04   Max: 620
Current: 421.9
4.04
620
P/B 2.33
VPHM's P/B is ranked higher than
70% of the 359 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. VPHM: 2.33 )
VPHM' s 10-Year P/B Range
Min: 0.45   Max: 3559
Current: 2.33
0.45
3559
P/S 4.61
VPHM's P/S is ranked higher than
68% of the 391 Companies
in the Global Biotechnology industry.

( Industry Median: 7.70 vs. VPHM: 4.61 )
VPHM' s 10-Year P/S Range
Min: 1.11   Max: 1050
Current: 4.61
1.11
1050
PFCF 540.80
VPHM's PFCF is ranked lower than
91% of the 129 Companies
in the Global Biotechnology industry.

( Industry Median: 30.73 vs. VPHM: 540.80 )
VPHM' s 10-Year PFCF Range
Min: 3.95   Max: 540.8
Current: 540.8
3.95
540.8
EV-to-EBIT -15.57
VPHM's EV-to-EBIT is ranked lower than
92% of the 266 Companies
in the Global Biotechnology industry.

( Industry Median: 21.21 vs. VPHM: -15.57 )
VPHM' s 10-Year EV-to-EBIT Range
Min: 2.9   Max: 54.8
Current: -15.57
2.9
54.8
Shiller P/E 40.09
VPHM's Shiller P/E is ranked lower than
100% of the Companies
in the Global Biotechnology industry.

( Industry Median: vs. VPHM: 40.09 )
VPHM' s 10-Year Shiller P/E Range
Min: 9.02   Max: 58.59
Current: 40.09
9.02
58.59

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 20.8
VPHM's Price/Net Current Asset Value is ranked higher than
72% of the 313 Companies
in the Global Biotechnology industry.

( Industry Median: 41.90 vs. VPHM: 20.8 )
VPHM' s 10-Year Price/Net Current Asset Value Range
Min: 12.5   Max: 573.8
Current: 20.8
12.5
573.8
Price/Tangible Book 40.9
VPHM's Price/Tangible Book is ranked lower than
95% of the 344 Companies
in the Global Biotechnology industry.

( Industry Median: 4.90 vs. VPHM: 40.9 )
VPHM' s 10-Year Price/Tangible Book Range
Min: 1.3   Max: 37.9
Current: 40.9
1.3
37.9
Price/DCF (Projected) 0.8
VPHM's Price/DCF (Projected) is ranked higher than
95% of the 66 Companies
in the Global Biotechnology industry.

( Industry Median: 2.40 vs. VPHM: 0.8 )
VPHM' s 10-Year Price/DCF (Projected) Range
Min: 0.4   Max: 3.7
Current: 0.8
0.4
3.7
Price/Median PS Value 1
VPHM's Price/Median PS Value is ranked higher than
52% of the 345 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. VPHM: 1 )
VPHM' s 10-Year Price/Median PS Value Range
Min: 0.4   Max: 26.1
Current: 1
0.4
26.1
Price/Peter Lynch Fair Value 22.3
VPHM's Price/Peter Lynch Fair Value is ranked lower than
766% of the 32 Companies
in the Global Biotechnology industry.

( Industry Median: 1.50 vs. VPHM: 22.3 )
VPHM' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.2   Max: 20.7
Current: 22.3
0.2
20.7
Price/Graham Number 24.1
VPHM's Price/Graham Number is ranked lower than
98% of the 140 Companies
in the Global Biotechnology industry.

( Industry Median: 2.50 vs. VPHM: 24.1 )
VPHM' s 10-Year Price/Graham Number Range
Min: 0.7   Max: 22.3
Current: 24.1
0.7
22.3
Earnings Yield (Greenblatt) 2.10
VPHM's Earnings Yield (Greenblatt) is ranked higher than
59% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 0.70 vs. VPHM: 2.10 )
VPHM' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.8   Max: 34.1
Current: 2.1
1.8
34.1
Forward Rate of Return (Yacktman) 4.79
VPHM's Forward Rate of Return (Yacktman) is ranked higher than
88% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. VPHM: 4.79 )
VPHM' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -131   Max: 46.8
Current: 4.79
-131
46.8

Business Description

ViroPharma, Inc. was incorporated in Delaware in September 1994 and commenced operations in December 1994. ViroPharma and subsidiaries is a biotechnology company dedicated to the development and commercialization of products that address serious diseases, with a focus on products used by physician specialists or in hospital settings. The Company's main development programs include C1 esterase inhibitor and a non-toxigenic strain of C. The Company markets and sells Cinryze in the United States for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema. Cinryze is a C1 esterase inhibitor therapy for routine prophylaxis against HAE, also known as C1 inhibitor deficiency, a rare, severely debilitating, life-threatening genetic disorder. Cinryze was obtained in October 2008, and On January 8, 2010 the company obtained expanded rights to commercialize Cinryze and future C1-INH derived products in certain European countries and other territories throughout the world as well as rights to develop future C1-INH derived products for additional indications. ViroPharma is currently evaluating its commercialization plans in additional territories. The Company also markets and sells Vancocin HCl capsules, the oral capsule formulation of vancomycin hydrochloride, in the U.S. and its territories. Vancocin is a potent antibiotic approved by the U.S. Food and Drug Administration, or FDA, to treat antibiotic-associated pseudomembranous colitis caused by Clostridium difficile infection, or C. difficile, and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. The Company's product development portfolio is mainly focused on three programs, C1 esterase inhibitor [human], VP20621 and VP-20629. The Company is working on developing further therapeutic uses; potential additional indications in other C1 mediated diseases, and alternative modes of administration for C1 esterase inhibitor. It is also developing VP20621 for the treatment and prevention of CDAD. In May 2011, it initiated a Phase 2 dose-ranging clinical study to evaluate the safety, tolerability, and efficacy of VP 20621 for prevention of recurrence of CDAD in adults previously treated for CDAD. On September 30, 2011, it entered into a license agreement for the worldwide rights of Intellect Neurosciences, Inc. (INS) to its clinical stage drug candidate, VP-20629, which is a naturally occurring, small molecule that has potent anti-oxidant properties that can protect against neurodegenerative disease. Its main competitors include both public and private entities, including well-known, large pharmaceutical companies, chemical companies, biotechnology companies and research institutions.
Company Website
SEC Reports
Industry: Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG
Traded in other countries:VPH.Germany
» More Articles for VPHM

Headlines

Articles On GuruFocus.com
Today’s Pronouncement: Value Investing Is A Lie Apr 17 2011 
Weekly CFO Sells Article: MERU, GPS, ALSK, VPHM, COF, TLAB Mar 20 2011 
ViroPharma Inc. (VPHM) VP, CFO Charles A Jr Rowland sells 35,000 Shares Mar 15 2011 
ViroPharma Inc. Reports Operating Results (10-K) Feb 24 2011 
ViroPharma Inc. Reports Operating Results (10-K/A) Dec 03 2010 
ViroPharma Inc. Reports Operating Results (10-Q) Oct 27 2010 
ViroPharma (VPHM) - A Tale of Two Drugs Aug 13 2010 
ViroPharma Inc. Reports Operating Results (10-Q) Jul 28 2010 
ViroPharma Inc. (VPHM) VP, COO Daniel B Soland buys 20,000 Shares May 07 2010 
ViroPharma Inc. Reports Operating Results (10-Q) Apr 28 2010 

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial